Shares of Whitehawk Therapeutics, Inc. (NASDAQ:WHWK – Get Free Report) have been given a consensus rating of “Moderate Buy” by the eight ratings firms that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating and seven have given a buy rating to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $8.33.
Several equities analysts have recently weighed in on WHWK shares. Stifel Nicolaus began coverage on Whitehawk Therapeutics in a research report on Wednesday, September 30th. They set a “buy” rating and a $9.00 target price on the stock. Wall Street Zen raised shares of Whitehawk Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Leerink Partners initiated coverage on Whitehawk Therapeutics in a report on Monday, July 13th. They issued an “outperform” rating and a $9.00 price target on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Whitehawk Therapeutics in a research note on Wednesday, September 2nd.
Check Out Our Latest Analysis on Whitehawk Therapeutics
Whitehawk Therapeutics Price Performance
Shares of NASDAQ WHWK opened at $3.17 on Monday. The business’s 50 day moving average is $3.75 and its two-hundred day moving average is $3.83. Whitehawk Therapeutics has a 1-year low of $1.97 and a 1-year high of $5.49.
Whitehawk Therapeutics (NASDAQ:WHWK – Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.10. On average, research analysts predict that Whitehawk Therapeutics will post -1.00 EPS for the current year.
Institutional Trading of Whitehawk Therapeutics
Hedge funds and other institutional investors have recently bought and sold shares of the business. Two Sigma Securities LLC purchased a new stake in shares of Whitehawk Therapeutics during the second quarter valued at $46,000. OMERS ADMINISTRATION Corp purchased a new position in Whitehawk Therapeutics in the 1st quarter worth about $40,000. Deutsche Bank AG purchased a new position in Whitehawk Therapeutics in the 2nd quarter worth about $145,000. Bank of America Corp DE purchased a new position in Whitehawk Therapeutics in the 2nd quarter worth about $159,000. Finally, Eversept Partners LP lifted its holdings in Whitehawk Therapeutics by 17.9% during the 1st quarter. Eversept Partners LP now owns 306,800 shares of the company’s stock valued at $1,058,000 after buying an additional 46,541 shares in the last quarter. Hedge funds and other institutional investors own 52.08% of the company’s stock.
About Whitehawk Therapeutics
Whitehawk Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel medicines for the treatment of serious diseases. The company’s activities center on advancing an internal pipeline of therapeutic candidates through preclinical research and clinical development.
Whitehawk Therapeutics does not appear to have marketed products at this stage. Its work is focused primarily on research and development, including evaluating potential drug candidates for safety, efficacy and suitability for further clinical testing.
Publicly available information about the company’s specific pipeline, operating geographies and leadership is limited.
See Also
- Five stocks we like better than Whitehawk Therapeutics
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for Whitehawk Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Whitehawk Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
